002022 科华生物
已收盘 07-17 15:00:00
资讯
新帖
简况
科华生物：公司自产产品、代理产品均采用“经销为主、直销为辅”的销售模式
证券之星 · 07-16 19:00
科华生物：公司自产产品、代理产品均采用“经销为主、直销为辅”的销售模式
科华生物（002022）7月10日主力资金净卖出732.49万元
证券之星 · 07-10
科华生物（002022）7月10日主力资金净卖出732.49万元
科华生物新提交1件商标注册申请
证券之星 · 07-10
科华生物新提交1件商标注册申请
科华生物最新公告：预计上半年净亏损4000万元-5700万元
证券之星 · 07-09
科华生物最新公告：预计上半年净亏损4000万元-5700万元
科华生物（002022）7月9日主力资金净买入72.10万元
证券之星 · 07-09
科华生物（002022）7月9日主力资金净买入72.10万元
7月4日科华生物创60日新低，财通资管健康产业混合A基金重仓该股
证券之星 · 07-04
7月4日科华生物创60日新低，财通资管健康产业混合A基金重仓该股
科华生物（002022）7月4日主力资金净卖出237.51万元
证券之星 · 07-04
科华生物（002022）7月4日主力资金净卖出237.51万元
科华生物接待4家机构调研，包括中信证券、睿郡资产、理成资产等
金融界 · 07-03
科华生物接待4家机构调研，包括中信证券、睿郡资产、理成资产等
科华生物：中信证券、睿郡资产等多家机构于7月3日调研我司
证券之星 · 07-03
科华生物：中信证券、睿郡资产等多家机构于7月3日调研我司
科华生物最新公告：近日获得两份医疗器械注册证
证券之星 · 07-02
科华生物最新公告：近日获得两份医疗器械注册证
科华生物(002022.SZ)两款产品获得医疗器械注册证
智通财经 · 07-02
科华生物(002022.SZ)两款产品获得医疗器械注册证
科华生物(002022.SZ)已累计回购2.11%股份 耗资约8424.6万元
智通财经网 · 07-01
科华生物(002022.SZ)已累计回购2.11%股份 耗资约8424.6万元
科华生物(002022.SZ)子公司拟以1534.40万欧元回购TGS20%股份
智通财经 · 06-27
科华生物(002022.SZ)子公司拟以1534.40万欧元回购TGS20%股份
科华生物：公司采取了多方面策略进行降本增效。在行业趋势的引领下，公司通过完善供应链来进行降本增效
证券之星 · 06-27
科华生物：公司采取了多方面策略进行降本增效。在行业趋势的引领下，公司通过完善供应链来进行降本增效
科华生物最新公告：子公司TGS以1534.4万欧元回购Altergon所持20%股份
证券之星 · 06-27
科华生物最新公告：子公司TGS以1534.4万欧元回购Altergon所持20%股份
科华生物：若公司半年度经营业绩符合业绩预告相关规定，公司将按照相关法律法规的规定及时履行信息披露义务
证券之星 · 06-25
科华生物：若公司半年度经营业绩符合业绩预告相关规定，公司将按照相关法律法规的规定及时履行信息披露义务
科华生物(002022.SZ)累计回购股份比例达2.04% 耗资8231.02万元
智通财经 · 06-21
科华生物(002022.SZ)累计回购股份比例达2.04% 耗资8231.02万元
科华生物：资产负债表中货币资金和交易性金融资产属于不同性质的报表项目，两者金额不存在交叉重叠
证券之星 · 06-18
科华生物：资产负债表中货币资金和交易性金融资产属于不同性质的报表项目，两者金额不存在交叉重叠
格力地产：公司将持有的上海科华生物工程股份有限公司股份作为长期股权投资进行会计核算
每日经济新闻 · 06-18
格力地产：公司将持有的上海科华生物工程股份有限公司股份作为长期股权投资进行会计核算
科华生物：太平洋证券、开源证券等多家机构于6月14日调研我司
证券之星 · 06-14
科华生物：太平洋证券、开源证券等多家机构于6月14日调研我司
加载更多
公司概况
公司名称：
上海科华生物工程股份有限公司
所属行业：
医药制造业
上市日期：
2004-07-21
主营业务：
上海科华生物工程股份有限公司主营业务是体外诊断试剂、医疗检验仪器的研发、生产和销售。公司的主要产品包括试剂类产品、仪器类产品，主要用于临床医院的化验检测，采供血系统献血员的筛选，以及边防海关、疾病预防控制系统的相关人群检测等。公司体外诊断仪器的技术水平始终处于国内领先地位。
发行价格：
11.12
{"stockData":{"symbol":"002022","market":"SZ","secType":"STK","nameCN":"科华生物","latestPrice":5.34,"timestamp":1721199828000,"preClose":5.33,"halted":0,"volume":3649083,"delay":0,"floatShares":513999999,"shares":513999999,"eps":-0.6176,"marketStatus":"已收盘","marketStatusCode":5,"change":0.01,"latestTime":"07-17 15:00:00","open":5.3,"high":5.39,"low":5.28,"amount":19486900,"amplitude":0.0206,"askPrice":5.34,"askSize":88,"bidPrice":5.33,"bidSize":127,"shortable":0,"etf":0,"ttmEps":-0.6176,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721266200000},"adr":0,"adjPreClose":5.33,"symbolType":"stock","openAndCloseTimeList":[[1721179800000,1721187000000],[1721192400000,1721199600000]],"highLimit":5.86,"lowLimit":4.8,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":514317273,"pbRate":0.7,"roa":"--","roe":"--","epsLYR":-0.455,"committee":-0.42599,"marketValue":2746000000,"floatMarketCap":2746000000,"peRate":-8.646373,"changeRate":0.0019,"turnoverRate":0.0071,"status":0},"requestUrl":"/m/hq/s/002022","defaultTab":"news","newsList":[{"id":"2451960320","title":"科华生物：公司自产产品、代理产品均采用“经销为主、直销为辅”的销售模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2451960320","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451960320?lang=zh_cn&edition=full","pubTime":"2024-07-16 19:00","pubTimestamp":1721127654,"startTime":"0","endTime":"0","summary":"证券之星消息，科华生物07月16日在投资者关系平台上答复投资者关心的问题。公司自产产品、代理产品均采用“经销为主、直销为辅”的销售模式。为适应体外诊断的行业发展趋势，结合体外诊断产品的结构特点，公司在国内外构建了广泛的经销商网络，拥有专业的营销队伍和完善的营销体系。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071600037391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002022","BK0028","BK0188","BK0046"],"gpt_icon":0},{"id":"2450851385","title":"科华生物（002022）7月10日主力资金净卖出732.49万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450851385","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450851385?lang=zh_cn&edition=full","pubTime":"2024-07-10 15:25","pubTimestamp":1720596320,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月10日收盘，科华生物报收于5.07元，下跌3.8%，换手率1.68%，成交量8.63万手，成交额4414.44万元。7月10日的资金流向数据方面，主力资金净流出732.49万元，占总成交额16.59%，游资资金净流出342.81万元，占总成交额7.77%，散户资金净流入1075.3万元，占总成交额24.36%。科华生物主营业务：体外诊断试剂、医疗检验仪器的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071000026969.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0046","BK0188","002022"],"gpt_icon":0},{"id":"2450834152","title":"科华生物新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2450834152","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450834152?lang=zh_cn&edition=full","pubTime":"2024-07-10 12:58","pubTimestamp":1720587510,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，近日上海科华生物工程股份有限公司新提交1件商标注册申请。商标申请详情如下：今年以来上海科华生物工程股份有限公司新申请注册商标5件，截止目前公司共持有注册商标154件，另有5件商标尚在注册申请中。数据来源：企查查以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071000025160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0239","002022","BK0046"],"gpt_icon":0},{"id":"2450021370","title":"科华生物最新公告：预计上半年净亏损4000万元-5700万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450021370","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450021370?lang=zh_cn&edition=full","pubTime":"2024-07-09 23:01","pubTimestamp":1720537282,"startTime":"0","endTime":"0","summary":"科华生物公告，预计上半年净利亏损4000万元-5700万元，上年同期盈利2112.81万元。受市场环境变化、行业竞争加剧、集采政策推行等因素影响，公司上半年业绩下降。同时，公司逆周期保持高比例研发投入，持续推动公司产品升级迭代、降本增效，布局新赛道、开拓新产品。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070900049979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","002022","BK0046","BK0239"],"gpt_icon":0},{"id":"2450968900","title":"科华生物（002022）7月9日主力资金净买入72.10万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450968900","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450968900?lang=zh_cn&edition=full","pubTime":"2024-07-09 15:25","pubTimestamp":1720509919,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月9日收盘，科华生物报收于5.27元，下跌1.31%，换手率1.83%，成交量9.39万手，成交额4887.94万元。近5日资金流向一览见下表：该股主要指标及行业内排名如下：科华生物2024年一季报显示，公司主营收入4.43亿元，同比下降46.79%；归母净利润-2882.15万元，同比下降152.63%；扣非净利润-3911.66万元，同比下降181.25%；负债率26.23%，投资收益236.67万元，财务费用608.15万元，毛利率42.05%。科华生物主营业务：体外诊断试剂、医疗检验仪器的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070900027014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"None","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0046","002022","BK0028"],"gpt_icon":0},{"id":"2448148124","title":"7月4日科华生物创60日新低，财通资管健康产业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448148124","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448148124?lang=zh_cn&edition=full","pubTime":"2024-07-04 16:22","pubTimestamp":1720081336,"startTime":"0","endTime":"0","summary":"证券之星消息，7月4日科华生物跌5.82%创60日新低，收盘报5.34元，换手率1.24%，成交量6.36万手，成交额3471.07万元。重仓科华生物的公募基金请见下表：根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为财通资管健康产业混合A。财通资管健康产业混合A目前规模为3.85亿元，最新净值0.846，较上一交易日下跌2.09%，近一年下跌24.67%。该公募基金现任基金经理为易小金。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070400030701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"None","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0046","002022","BK0028"],"gpt_icon":0},{"id":"2448341371","title":"科华生物（002022）7月4日主力资金净卖出237.51万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448341371","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448341371?lang=zh_cn&edition=full","pubTime":"2024-07-04 15:26","pubTimestamp":1720077966,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月4日收盘，科华生物报收于5.34元，下跌5.82%，换手率1.24%，成交量6.36万手，成交额3471.07万元。近5日资金流向一览见下表：该股主要指标及行业内排名如下：科华生物2024年一季报显示，公司主营收入4.43亿元，同比下降46.79%；归母净利润-2882.15万元，同比下降152.63%；扣非净利润-3911.66万元，同比下降181.25%；负债率26.23%，投资收益236.67万元，财务费用608.15万元，毛利率42.05%。科华生物主营业务：体外诊断试剂、医疗检验仪器的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070400024761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002022","BK0046","BK0239","BK0188"],"gpt_icon":0},{"id":"2448486404","title":"科华生物接待4家机构调研，包括中信证券、睿郡资产、理成资产等","url":"https://stock-news.laohu8.com/highlight/detail?id=2448486404","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448486404?lang=zh_cn&edition=full","pubTime":"2024-07-03 22:06","pubTimestamp":1720015570,"startTime":"0","endTime":"0","summary":"2024年7月3日， 科华生物 披露接待调研公告，公司于7月3日接待 中信证券 、睿郡资产、理成资产、 东方财富 4家机构调研。公告显示，科华生物参与本次接待的人员共1人，为证券事务代表陈兴龙。此外，科华生物在宠物检测市场方面，已有分子生物学平台，可用于检测宠物传染病。科华生物拟使用自有资金以集中竞价交易方式回购公司股份，用于股权激励或员工持股计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703221828956e501f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703221828956e501f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["002022","LU1997245177.USD","LU1328615791.USD","BK0239","BK0276","LU0405327494.USD","LU1997245094.SGD","BK0046","BK0196","BK0028","BK0012","LU1064131003.USD","600030","LU1064130708.USD","LU2148510915.USD","LU0405327148.USD","BK0183","BK0188","06030"],"gpt_icon":0},{"id":"2448722991","title":"科华生物：中信证券、睿郡资产等多家机构于7月3日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2448722991","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448722991?lang=zh_cn&edition=full","pubTime":"2024-07-03 17:54","pubTimestamp":1720000450,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年7月3日科华生物发布公告称中信证券李天雄、睿郡资产丁晨霞、理成资产陶然 陈颖、东方财富朱张元于2024年7月3日调研我司。公司经过在体外诊断行业 40 余年积累，公司及子公司产品已出口至海外 100 多个国家和地区。购股份期限为自董事会审议通过购股份方案之日起 12个月内。若有相关投资并购计划，公司将严格按照相关法规履行信息披露义务。科华生物主营业务：体外诊断试剂、医疗检验仪器的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070300037406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","LU1997245177.USD","BK0188","LU2148510915.USD","BK0183","BK0239","BK1521","LU1064131003.USD","BK1516","BK1564","BK0196","LU1064130708.USD","LU1328615791.USD","LU0405327148.USD","LU1720050803.USD","002022","BK0276","06030","BK0028","LU1794554557.SGD","BK1147","LU0405327494.USD","LU1997245094.SGD","600030","BK0046"],"gpt_icon":0},{"id":"2448918418","title":"科华生物最新公告：近日获得两份医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2448918418","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448918418?lang=zh_cn&edition=full","pubTime":"2024-07-02 16:10","pubTimestamp":1719907857,"startTime":"0","endTime":"0","summary":"科华生物公告，近日，公司及全资子公司上海科华实验系统有限公司分别收到上海市药品监督管理局颁发的医疗器械注册证。产品名称：反三碘甲状腺原氨酸测定试剂盒(化学发光法)、模块化生化免疫分析系统。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070200022988.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK0046","159883","002022","BK1574","BK1100","BK0239","BK0028","09997","BK1222","09996","BK0188"],"gpt_icon":0},{"id":"2448899941","title":"科华生物(002022.SZ)两款产品获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2448899941","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448899941?lang=zh_cn&edition=full","pubTime":"2024-07-02 15:45","pubTimestamp":1719906352,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科华生物(002022.SZ)发布公告，近日，公司及全资子公司上海科华实验系统有限公司分别收到上海市药品监督管理局颁发的医疗器械注册证，涉及产品：“反三碘甲状腺原氨酸测定试剂盒(化学发光法)”、“模块化生化免疫分析系统”。以上新产品医疗器械注册证的取得，丰富了公司产品线，将对公司业务发展具有正面影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1144260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1222","BK1100","BK0028","BK1583","BK1574","BK0188","09997","BK0239","159883","09996","002022","BK0046"],"gpt_icon":0},{"id":"2448396954","title":"科华生物(002022.SZ)已累计回购2.11%股份 耗资约8424.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448396954","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448396954?lang=zh_cn&edition=full","pubTime":"2024-07-01 16:47","pubTimestamp":1719823620,"startTime":"0","endTime":"0","summary":"科华生物(002022.SZ)发布公告，截至2024年6月30日，公司累计通过股份回购专用证券账户以集中竞价交易方式回购公司股份数量为1083.28万股，占公司目前总股本的比例2.11%，最高成交价格10.68元/股，最低成交价格为5.62元/股，成交金额为8424.6万元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-01/doc-incarnkf1443876.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-07-01/doc-incarnkf1443876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0188","002022","BK0028","BK0046"],"gpt_icon":0},{"id":"2446539679","title":"科华生物(002022.SZ)子公司拟以1534.40万欧元回购TGS20%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2446539679","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446539679?lang=zh_cn&edition=full","pubTime":"2024-06-27 20:08","pubTimestamp":1719490090,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科华生物 发布公告，公司全资子公司科华生物国际有限公司目前持有控股子公司Technogenetics S.P.A.80%股份，非关联方Altergon Italia S.r.l.持有TGS20%股份。近年来，TGS充分发挥其在欧洲地区的销售网络优势，助力公司开拓国际市场。为进一步增强公司核心竞争力，经各方友好协商确定，TGS、科华国际与Altergon于2024年6月26日经公证签署了《SALE AND PURCHASE AGREEMENT》，约定TGS以1534.40万欧元回购Altergon持有的TGS20%股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1141859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK0028","BK0188","BK0239","002022"],"gpt_icon":0},{"id":"2446953964","title":"科华生物：公司采取了多方面策略进行降本增效。在行业趋势的引领下，公司通过完善供应链来进行降本增效","url":"https://stock-news.laohu8.com/highlight/detail?id=2446953964","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446953964?lang=zh_cn&edition=full","pubTime":"2024-06-27 20:00","pubTimestamp":1719489623,"startTime":"0","endTime":"0","summary":"证券之星消息，科华生物06月27日在投资者关系平台上答复投资者关心的问题。公司采取了多方面策略进行降本增效。在行业趋势的引领下，公司通过完善供应链来进行降本增效。同时，公司持续提升质量体系，推动产品升级迭代，并推进自动化、数字化、智慧化战略落地，从产品生产的全流程进行降本增效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062700037555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002022","BK0046","BK0188"],"gpt_icon":0},{"id":"2446885580","title":"科华生物最新公告：子公司TGS以1534.4万欧元回购Altergon所持20%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2446885580","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446885580?lang=zh_cn&edition=full","pubTime":"2024-06-27 18:39","pubTimestamp":1719484778,"startTime":"0","endTime":"0","summary":"科华生物公告，为进一步增强公司核心竞争力，经各方友好协商确定，子公司TGS、科华国际与Altergon于2024年6月26日经公证签署了《SALE AND PURCHASE AGREEMENT》，约定TGS以1534.4万欧元回购Altergon持有的TGS20%股份。交易完成后，TGS将成为公司的全资子公司。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062700034690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["MEURmain","BK0046","BK0028","BK0188","BK0239","FXE","002022","EUO","EURmain"],"gpt_icon":0},{"id":"2446819726","title":"科华生物：若公司半年度经营业绩符合业绩预告相关规定，公司将按照相关法律法规的规定及时履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2446819726","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446819726?lang=zh_cn&edition=full","pubTime":"2024-06-25 19:00","pubTimestamp":1719313256,"startTime":"0","endTime":"0","summary":"证券之星消息，科华生物06月25日在投资者关系平台上答复投资者关心的问题。投资者：截止一季，科华生物账上有17亿现金和理财；是否考虑估计先下修到净资产7.8左右，再宣布再拿6个亿现金加上还没有用完的1个多亿现金在不超过10元的价格回购股份，回购股份用于支付可转债转股。若公司半年度经营业绩符合业绩预告相关规定，公司将按照相关法律法规的规定及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062500035798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"None","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002022","BK0046","BK0188","BK0028"],"gpt_icon":0},{"id":"2445173961","title":"科华生物(002022.SZ)累计回购股份比例达2.04% 耗资8231.02万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2445173961","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445173961?lang=zh_cn&edition=full","pubTime":"2024-06-21 17:21","pubTimestamp":1718961677,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科华生物(002022.SZ)公告，截至2024年6月20日，公司累计通过股份回购专用证券账户以集中竞价交易方式回购公司股份数量为1049.09万股，占公司目前总股本的比例2.04%，最高成交价格10.68元/股，最低成交价格为5.85元/股，成交金额为8231.02万元(不含交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1138627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","BK0046","002022","BK0188"],"gpt_icon":0},{"id":"2444543439","title":"科华生物：资产负债表中货币资金和交易性金融资产属于不同性质的报表项目，两者金额不存在交叉重叠","url":"https://stock-news.laohu8.com/highlight/detail?id=2444543439","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444543439?lang=zh_cn&edition=full","pubTime":"2024-06-18 23:00","pubTimestamp":1718722835,"startTime":"0","endTime":"0","summary":"证券之星消息，科华生物06月18日在投资者关系平台上答复投资者关心的问题。截至2024年5月31日，公司累计通过股份回购专用证券账户以集中竞价交易方式回购公司股份数量为9,387,800股，占公司目前总股本的比例1.83%。投资者：请问科华生物一季度报表反应货币资金13.79亿，交易性金融资产3.033亿。资产负债表中货币资金和交易性金融资产属于不同性质的报表项目，两者金额不存在交叉重叠。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061800040948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0046","002022","BK0239","BK0028"],"gpt_icon":0},{"id":"2444107414","title":"格力地产：公司将持有的上海科华生物工程股份有限公司股份作为长期股权投资进行会计核算","url":"https://stock-news.laohu8.com/highlight/detail?id=2444107414","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444107414?lang=zh_cn&edition=full","pubTime":"2024-06-18 18:09","pubTimestamp":1718705376,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：贵司作为科华生物的第一大股东实控人，对于目前科华股价不断下跌的情况，有无增持计划？格力地产（600185.SH）6月18日在投资者互动平台表示，公司将持有的上海科华生物工程股份有限公司股份作为长期股权投资进行会计核算，目前并不是科华生物的第一大股东或实际控制人。(记者 蔡鼎)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061818095795bd42f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061818095795bd42f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["002022","BK0046","BK0273","BK0188","BK0201","600185","BK0239","BK0028","BK0012","BK0173"],"gpt_icon":0},{"id":"2443864685","title":"科华生物：太平洋证券、开源证券等多家机构于6月14日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2443864685","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443864685?lang=zh_cn&edition=full","pubTime":"2024-06-14 16:52","pubTimestamp":1718355160,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年6月14日科华生物发布公告称太平洋证券张健、开源证券王洁于2024年6月14日调研我司。公司经过在体外诊断行业 40 余年积累，公司及子公司产品已出口至海外 100 多个国家和地区。科华生物2024年一季报显示，公司主营收入4.43亿元，同比下降46.79%；归母净利润-2882.15万元，同比下降152.63%；扣非净利润-3911.66万元，同比下降181.25%；负债率26.23%，投资收益236.67万元，财务费用608.15万元，毛利率42.05%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061400031355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0276","601099","BK0028","BK0183","002022","BK0239","BK0046","161027","BK0077","BK0188","BK0201"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2004-07-21","address":"上海市徐汇区钦州北路1189号","stockEarnings":[{"period":"1week","weight":0.0114},{"period":"1month","weight":-0.119},{"period":"3month","weight":-0.2275},{"period":"6month","weight":-0.4078},{"period":"1year","weight":-0.4488},{"period":"ytd","weight":-0.5316}],"companyName":"上海科华生物工程股份有限公司","boardCode":"AI0027","perCapita":"11090股","boardName":"医药制造业","registeredCapital":"51431万元","compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0186},{"period":"3month","weight":-0.031},{"period":"6month","weight":0.0459},{"period":"1year","weight":-0.0727},{"period":"ytd","weight":0.0005}],"survey":" 上海科华生物工程股份有限公司主营业务是体外诊断试剂、医疗检验仪器的研发、生产和销售。公司的主要产品包括试剂类产品、仪器类产品，主要用于临床医院的化验检测，采供血系统献血员的筛选，以及边防海关、疾病预防控制系统的相关人群检测等。公司体外诊断仪器的技术水平始终处于国内领先地位。","serverTime":1721207937385,"listedPrice":11.12,"stockholders":"46370人(较上一季度减少72.26%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.0","shortVersion":"4.25.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科华生物(002022)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科华生物(002022)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科华生物,002022,科华生物股票,科华生物股票老虎,科华生物股票老虎国际,科华生物行情,科华生物股票行情,科华生物股价,科华生物股市,科华生物股票价格,科华生物股票交易,科华生物股票购买,科华生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科华生物(002022)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科华生物(002022)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}